Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study

Pharmacotherapy
Rolf P KreutzDavid A Flockhart

Abstract

To investigate the potential impact of proton pump inhibitors (PPIs) on the effectiveness of clopidogrel in preventing recurrent ischemic events after percutaneous coronary intervention (PCI) with stent placement. Population-based, retrospective cohort study. National medical and pharmacy benefit claims database comprising approximately 19 million members. A total of 16,690 patients who had undergone PCI with stent placement and who were highly adherent to clopidogrel therapy alone (9862 patients) or to clopidogrel with a PPI (6828 patients) between October 1, 2005, and September 30, 2006. The primary end point was the occurrence of a major adverse cardiovascular event during the 12 months after stent placement. These events were defined as hospitalization for a cerebrovascular event (stroke or transient ischemic attack), an acute coronary syndrome (myocardial infarction or unstable angina), coronary revascularization (PCI or coronary artery bypass graft), or cardiovascular death. A composite event rate was compared between patients who received clopidogrel alone and those who received concomitant clopidogrel-PPI therapy. Baseline differences in covariates were adjusted by using Cox proportional hazards models. In the 9862 pati...Continue Reading

References

Jan 1, 1997·Journal of Clinical Epidemiology·J F Steiner, A V Prochazka
Sep 12, 2002·Clinical Pharmacokinetics·Zeruesenay DestaDavid A Flockhart
Mar 16, 2004·Pharmacogenomics·Takahisa FurutaTakashi Ishizaki
Sep 13, 2008·Journal of the American College of Cardiology·Edmund PezallaIndira Pulliadath
Dec 25, 2008·The New England Journal of Medicine·Tabassome SimonUNKNOWN French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators
Dec 25, 2008·The New England Journal of Medicine·Jessica L MegaMarc S Sabatine
Jan 30, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·David N JuurlinkMuhammad M Mamdani
Mar 5, 2009·JAMA : the Journal of the American Medical Association·P Michael HoJohn S Rumsfeld

❮ Previous
Next ❯

Citations

Feb 22, 2012·Journal of Cardiovascular Translational Research·Atif MohammadSubhash Banerjee
Dec 21, 2010·Nature Reviews. Cardiology·Paul A Gurbel, Udaya S Tantry
Oct 16, 2010·Current Opinion in Gastroenterology·Siew C Ng, Francis K L Chan
Jan 31, 2012·Journal of Gastroenterology and Hepatology·Ping-I Hsu
Dec 8, 2010·BMC Medicine·Joao Paulo de Aquino Lima, James M Brophy
Aug 9, 2011·Drug Metabolism and Drug Interactions·Sandra L Close
Oct 13, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Saihari Sadanandan, Inder M Singh
Mar 17, 2010·Future Cardiology·Kathryn M Momary, Michael P Dorsch
May 23, 2012·World Journal of Gastroenterology : WJG·Michael D DrepperJean Louis Frossard
Jun 15, 2011·World Journal of Cardiology·Shoa-Lin LinJaw-Wen Chan
Jul 31, 2012·Pharmacogenomics·Rashmi R Shah, Robert L Smith
Sep 14, 2013·Internal and Emergency Medicine·Emilia D'UgoRaffaele De Caterina
Mar 16, 2011·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Juliana L MeyersYanni F Yu
Sep 6, 2014·European Journal of Clinical Pharmacology·Johan HolmBuster Mannheimer
Oct 19, 2012·Current Opinion in Cardiology·Jeremiah P Depta, Deepak L Bhatt
Jan 10, 2012·Journal of Clinical Gastroenterology·Joan ChenColin W Howden
Sep 3, 2014·Critical Reviews in Clinical Laboratory Sciences·Bridget L Morse, Richard B Kim
Sep 1, 2011·Expert Review of Cardiovascular Therapy·Isabell BernlochnerDirk Sibbing
Apr 8, 2014·Expert Review of Clinical Pharmacology·Naiem T IssaSivanesan Dakshanamurthy
Nov 12, 2013·Expert Opinion on Drug Metabolism & Toxicology·Stuart A ScottJean-Sébastien Hulot
Oct 4, 2011·Drug Discovery Today·Felix W Frueh
Sep 29, 2011·Gastrointestinal Endoscopy Clinics of North America·Grigorios I LeontiadisColin W Howden
Jan 22, 2011·Pharmacoepidemiology and Drug Safety·Tobias Gerhard
Nov 19, 2010·Alimentary Pharmacology & Therapeutics·V E ValkhoffM C J M Sturkenboom
Jan 19, 2012·Anaesthesia·R LandauJ C Kraft
Jul 27, 2010·Pharmacotherapy·Kathryn Momary, Larisa H Cavallari
Mar 30, 2010·Cardiovascular Therapeutics·Michael A Gaglia, Ron Waksman
Jun 11, 2014·British Journal of Clinical Pharmacology·Rashmi R Shah, Robert L Smith
Jan 21, 2011·The American Journal of Cardiology·Subhash BanerjeeDeepak L Bhatt
Mar 12, 2011·Journal of the American College of Cardiology·Eric R BatesDominick J Angiolillo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.